Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

February 15, 2021

Study Completion Date

February 8, 2022

Conditions
Tuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MDRTuberculosisExtensively Drug-Resistant TuberculosisPre-XDR-TBXDR-TB
Interventions
DRUG

Pretomanid

200mg tablets

DRUG

Linezolid

Scored 600mg tablets

DRUG

Bedaquiline

100mg tablets

DRUG

Placebo Linezolid

Scored 600 mg tablets

Trial Locations (11)

2025

Institute of Phthisiopneumology Chiril Draganiuc, Chisinau

2131

Clinical HIV Research Unit (CHRU) Sizwe Tropical Diseases Hospital, Johannesburg

2574

Tshepong Hospital, Klerksdorp

4015

King DinuZulu Hospital Complex, Durban

107014

Moscow City Research and Practice Tuberculosis Treatment Centre, Moscow

107564

Central TB Research Institute of the Federal Agency of Scientific Organizations Moscow, Moscow

191036

"FSBI Saint-Petersburg Research Institute of Phthisiopulmonology", Saint Petersburg

620039

Ural Research Institute of Phthisiopulmonology, Yekaterinburg

0101

National Center for Tuberculosis and Lung Diseases, Tbilisi

Unknown

National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow

Empilweni TB Hospital, Port Elizabeth

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER

NCT03086486 - Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis | Biotech Hunter | Biotech Hunter